<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266734</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 03-543E</org_study_id>
    <secondary_id>St John's IRB# 00003995</secondary_id>
    <secondary_id>Colorado HSC IRB# 05-0151</secondary_id>
    <nct_id>NCT00266734</nct_id>
  </id_info>
  <brief_title>Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears</brief_title>
  <official_title>A Prospective Blinded Multi-center Clinical Trial to Evaluate the Efficacy of the Recently FDA Approved RPS Adeno Detector for Detecting Adenoviral Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid Pathogen Screening</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RapidPS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of a recently FDA approved point of care diagnostic test, the RPS&#xD;
      Adeno Detector (Rapid Pathogen Screening, Inc.; South Williamsport, PA), against cell culture&#xD;
      for detecting adenoviral conjunctivitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date>September 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to accurately detect presence or absence of adenovirus in conjunctival specimens</measure>
  </primary_outcome>
  <enrollment>186</enrollment>
  <condition>Acute Conjunctivitis</condition>
  <condition>Adenoviral Conjunctivitis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RPS Adeno Detector</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Clinical Study Enrollment Criteria&#xD;
&#xD;
        Upon completing the in-vitro studies, a perspective, blinded clinical study was started.&#xD;
        Patients who were older than 1 month of age, seen within 7 days of developing a red eye,&#xD;
        and who demonstrate at least one criterion from two out of the three categories below were&#xD;
        included:&#xD;
&#xD;
        I. History: 1) Spread from one eye to the other several days later, 2) recent or concurrent&#xD;
        upper respiratory symptoms within the preceding two weeks, 3) or an exposure to someone&#xD;
        with &quot;pink eye&quot; within the preceding three weeks&#xD;
&#xD;
        II. Symptoms: 1) Tearing, 2) mucoid or purulent discharge, 3) eye lash matting, 4) burning,&#xD;
        5) itching, or 6) foreign body sensation&#xD;
&#xD;
        III. Signs: 1) An inferior palpebral conjunctival reaction with &gt; or = 1+ papillary or&#xD;
        follicular reactions, 2) presence of a preauricular node&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with associated skin vesicles, corneal dendrites, traumatic corneal abrasion,&#xD;
        concurrent corneal ulcers, foreign bodies, ocular pemphigoid, trauma, previous history of&#xD;
        chemical/thermal injury to eyes or eyelids (anytime in past), or greater than trace&#xD;
        intraocular inflammation were excluded from the study. Additionally, patients with allergy&#xD;
        to corn starch, talcum powder, or dacron were also be excluded. Patients using any topical&#xD;
        ophthalmic medication (i.e. antibiotics) were required to wait at least 30 minutes from&#xD;
        their last dose prior to device application and wait at least 2 hours after their last dose&#xD;
        of any ointment application&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth J Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shachar Tauber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Johns Ophthalmology Clinic, Springfield, MO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Schirra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit채tsklinikum des Saarlandes, Klinik f체r Augenheilkunde, Homburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian Kozich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nurnberg, Erlangen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Health Science Center, Denver, CO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Science Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Johns Ophthalmology Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Erlangen-Nurnberg</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit채tsklinikum des Saarlandes, Klinik f체r Augenheilkunde</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>December 16, 2005</study_first_submitted>
  <study_first_submitted_qc>December 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2005</study_first_posted>
  <last_update_submitted>February 9, 2010</last_update_submitted>
  <last_update_submitted_qc>February 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Sambursky</name_title>
    <organization>Rapid Pathogen Screening, Inc</organization>
  </responsible_party>
  <keyword>Adenoviral conjunctivitis</keyword>
  <keyword>Viral conjunctivitis</keyword>
  <keyword>conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Inclusion</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

